Second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer

Ítems similars

• Response to second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer: make no assumptions
  per: Karam, I., et al.
  Publicat: (2012)
• Predictive factors in patients with EGFR mutation-negative non-small cell lung cancer treated with erlotinib
  per: ISHII, HIDENOBU, et al.
  Publicat: (2014)
• Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients
  per: Liao, Bin-Chi, et al.
  Publicat: (2019)
• Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib
  per: Costa, Daniel B., et al.
  Publicat: (2008)
• Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors
  per: Hirsh, Vera
  Publicat: (2018)